|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2009-10-12
|
|
pubmed:abstractText |
Allopurinol was administered to end-stage renal disease (ESRD) patients with elevated uric acid levels presenting with symptoms of gout and also had risk factors of metabolic syndrome. The primary aim of this pilot study was to examine the effects of lowering uric acid levels using allopurinol on lipoprotein markers of metabolic syndrome in patients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1308-0032
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
385-9
|
|
pubmed:dateRevised |
2010-6-15
|
|
pubmed:meshHeading |
pubmed-meshheading:19819789-Adult,
pubmed-meshheading:19819789-Allopurinol,
pubmed-meshheading:19819789-Cholesterol, HDL,
pubmed-meshheading:19819789-Cholesterol, LDL,
pubmed-meshheading:19819789-Diabetes Mellitus, Type 2,
pubmed-meshheading:19819789-Female,
pubmed-meshheading:19819789-Gout Suppressants,
pubmed-meshheading:19819789-Humans,
pubmed-meshheading:19819789-Kidney Failure, Chronic,
pubmed-meshheading:19819789-Male,
pubmed-meshheading:19819789-Metabolic Syndrome X,
pubmed-meshheading:19819789-Middle Aged,
pubmed-meshheading:19819789-Pilot Projects,
pubmed-meshheading:19819789-Renal Dialysis,
pubmed-meshheading:19819789-Triglycerides,
pubmed-meshheading:19819789-Uric Acid
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study.
|
|
pubmed:affiliation |
Baylor University, School of Education, Waco, Texas, USA.
|
|
pubmed:publicationType |
Journal Article
|
